Following a Food and Drug Administration (FDA) 515 Program Intiative Advisory Panel meeting and vote on retaining the Class III designation of Abiomed, Inc.’s (NASDAQ: ABMD) (“Abiomed”) Impella 2.5 system, Hagens Berman Sobol Shapiro, LLP, a securities class-action law firm, reminds investors of the Jan. 15, 2013, deadline to seek the position of lead plaintiff in a lawsuit filed on behalf of investors.
Firefox recommends the PDF Plugin for Mac OS X for viewing PDF documents in your browser.
We can also show you Legal Updates using the Google Viewer; however, you will need to be logged into Google Docs to view them.
Please choose one of the above to proceed!
LOADING PDF: If there are any problems, click here to download the file.
Published In:
Health Law Updates, Securities Law Updates
DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.
© Steve Berman, Hagens Berman | Attorney Advertising
